News (Archive):

Prolab Nutrition Does Arnold Classic 2009.... (February 27,2009)
Believe it or not but there was a time when fans went nuts at the Prolab booth no matter what show it was put up at......

Indian Ownership In Natrol’s Future.... (November 26,2007)
It’s been years since Wall Street has valued Natrol Inc. as highly as founder Elliott Balbert believed it was worth. Now, a company halfway across the world has taken advantage of that weakness to gain a toehold in the huge U.S. nutritional supplements market......

Plethico Pharma Buys Natrol For $4.40 Per Share.... (December 28,2007)
Plethico Pharmaceuticals Limited said it closed the purchase of Natrol Inc., a California-based manufacturer of dietary supplements and sports nutrition products......

Plethico buys US company for $81 mn.... (November 20,2007)
Plethico Pharmaceuticals, a leading Indian herbal and nutraceutical (a combination of drug and food products) company, has agreed to acquire Natrol, a nutritional products company in the US, for $81 million (Rs 318 crore).......

Plethico Pharmaceuticals to acquire Natrol.... (November 20,2007)
India-based Plethico pharmaceuticals has agreed to acquire Natrol, manufacturer and marketer of nationally branded nutritional products in the US, for approximately $80.7 million.......

Plethico Pharma acquires US-based Natrol.... (November 19,2007)
Plethico Pharmaceuticals on Monday said it will acquire US-based Natrol Inc for 80.7 million dollars (Rs. 317.07 crore) to consolidate its position as a global player in herbal healthcare products......

India's Plethico Pharmaceuticals to acquire Natrol of US for 80.7 mln usd.... (November 19,2007)
India's Plethico Pharmaceuticals Ltd said it has agreed to acquire US-based nutritional products maker Natrol Inc for 80.7 mln usd.......

Plethico Launches $81M Offer for Natrol.... (November 19,2007)
Shares of Natrol Inc. soared in premarket trading Monday after an Indian company launched a tender offer to buy the health products maker for about $80.8 million......

Plethico Pharmaceuticals to acquire USA's Natrol, Inc..... (November 18,2007)
Plethico Pharmaceuticals Ltd has announced that on November 18, 2007 it has agreed to acquire Natrol, Inc., a leading manufacturer and marketer of nationally branded nutritional products in the United States of America.......

Mid-cap CBs return (October 26,2007)
Bookrunner Citi successfully completed a US$75m five-year CB for Indian mid-cap Plethico Pharmaceuticals that was backed by an interesting structure.....

Plethico raises USD 75 mn via FCCBs (October 16,2007)
Plethico Pharmaceuticals Ltd on October 16, 2007 has announced that it has successfully priced an offering of US$ 75 million....

Plethico Q3 net profit up at Rs 32.6 cr (July 18,2007)
Plethico declared its Q3 results. The company has posted net profit of 32.6 crore....

Snapshot - Brief Financials (July 18,2007)
Plethico Pharmaceuticals Limited (Plethico) is a pharmaceuticals manufacturing company established in 1963. The company is involved in pharmaceutical manufacturing research and development, contract manufacturing and marketing and distribution.....

De-mythifying ayurveda: Express Pharma (July 11,2007)
While some believe that ayurveda provides miraculous cures, others question its authenticity and safety....

Buy Plethico Pharma: KEYNOTE (April 20,2007)
Broking house, KEYNOTE is bullish on Plethico Pharmaceuticals and has maintained buy rating on the stock....

Buy Plethico Pharma; target of Rs 450: Finquest (April 18,2007)
Finquest is bullish on Plethico Pharma and has maintained buy rating with a 12 month target of Rs 450.....

Plethico Pharmaceuticals to sell stake in subsidiary companies
Plethico Pharmaceuticals Ltd has announced that the Board of Directors of the Company at its meeting held on March 12, 2007 has considered the proposals and taken the following decisions:...

Gusher of a Time
Plethico Pharmaceuticals has positioned itself as a player in the herbal and nutraceuticals segment and has over 400 different formulations in more than 39 therapeutic segments...

Plethico Pharma FY06 net up 38.5% at Rs 25.9cr
Plethico Pharma has announced its fourth quarter results. The company's FY06 net profit was up 38.5% from Rs 18.7 crore (Rs 187 million) to Rs 25.9 crore (Rs 259 million)...

Plethico Pharma board recommends 25% dividend
In a meeting held on Dec. 28, 2006, the board of directors of Plethico Pharmaceuticals recommended a dividend at the rate of 25% that is Rs 2.5 per share for the year ended on Sep. 30, 2006...

Plethico : Herbal Push
Plethico Pharmaceuticals benefited from improved demand conditions for its repertoire of herbal-based medications for treating lifestyle-related disorder such as diabetes and cholesterol in the year ended September 2006...

Expects 30% plus growth in FY07
Plethico Pharma has come out with its Q4 results. The company's FY06 net profit was up 38.5% from Rs 18.7 crore to Rs 25.9 crore. Its revenues were up 163.5% from Rs 61.1 crore to Rs 161 crore...

Plethico quarterly profit rises on export growth
Herbal drugs and nutritional products maker Plethico Pharmaceuticals Ltd. on Thursday posted a 38% rise in quarterly profit driven by increased exports and contract manufacturing revenue...

Plethico Pharmaceuticals Q3 FY06 net profit up 39% at Rs 23.33 cr
The Board of Directors of Plethico Pharmaceuticals Ltd, one of India.s fastest growing pharmaceutical companies in the herbal and nutraceuticals sector, today approved and adopted its financial results for the third quarter ended June 30, 2006 ...

42 join billionaire club post-IPO
Forty-two new members joined the billionaire club in the calendar year 2006 after their initial public offerings, IPO. Forty members joined the club on the day of the listing, while two others joined the elite club some time after the listing, reports The Hindu Business Line. ...

Plethico Pharmaceuticals IPO subscribed 25.63 times
Plethico Pharmaceuticals has closed its IPO and has been subscribed 25.63 times. The issue was through 100 percent book-built route. The qualified institutuional buyers, QIBs, portion has been subscribed 25.32 times. The non-institutional investors portion was subscribed 45.84 times. The retail investor's portion has been subscribed 19.53 times ...

Invest at cut-off
Track record of healthy profitability and an established presence in export markets with a product profile that is unlikely to be hurt by legal challenges make this offer attractive. Invest with a one/two-year perspective ...

Plethico Pharmaceuticals IPO poll: Experts say apply
Plethico Pharmaceuticals IPO opened today for subscription. Moneycontrol conducted a poll on market experts to check whether to apply for the public issue or not. Experts said apply. ...

Plethico Pharma: Looks promising
Looking at the response that the company would get, I recommend subscribing its IPO, which closes on April 17 with a price objective of about Rs 425-Rs 450 in less than twelve months. ...

A healthy option
Herbal drugs company Plethico Pharma has approached the capital market with a Rs 110-crore initial public offering (IPO) with a price band of Rs 280 to Rs 300 per share. The IPO opens today and will close on April 17. Retail investors can consider subscribing to the issue since the company is attractively priced compared to industry peers ...

Subscribe to Plethico Pharma IPO for long term: Keynote
Plethico Pharmaceuticals has opened for subscription through 100% book-built initial public offer. Keynote Capitals says that investors should subscribe to this issue with a medium to long term view. ...

Your IPO Watch - Plethico Pharmaceuticals Ltd. - Subscribe
PPL has been a consistent profit making company with high operating and net profit margins. However, the growth in the revenues seems to be slow and inconsistent. At the higher price band of Rs 300, on an annualised EPS for FY06E, the issue is priced at around 14x on a post equity basis which is rather attractive. ...

Plethora of opportunities
Plethico Pharma does not seem a bad bet considering the valuation of its peers. ...

IPO Profile
Plethico Pharma was established in 1985. It produces a wide range of products such as anti-malarial, anti-tubercular, anti-asthmatics, antibiotics, Naiads, Nutraceutical, antiinvectives, anti-bacterial, etc. ...

A quick look at Plethico Pharmaceuticals IPO
Plethico Pharmaceuticals, one of India’s fastest growing pharmaceutical companies in the herbal and nutraceuticals space having global presence, will open for subscription on April 10, 2006 through 100% book-built initial public offer. Take a quick look at its issue ...

Plethico sets initial offer at 280-300 rupees/shr
Plethico Pharmaceuticals Ltd. said on Tuesday it had fixed the price band for its 1.1-billion -rupee initial public offering at 280-300 rupees a share ...

Plethico Pharma IPO price band fixed at Rs 280-300
The 100% book-built initial Public Offer (IPO) of Plethico Pharmaceuticals Ltd. will open for subscription on April 10, 2006 and close on April 17, 2006 ...

Plethico Pharmaceuticals IPO opens on April 10
The 100% book-built Initial Public Offer (IPO) of Plethico Pharmaceuticals Ltd. will open for subscription on April 10, 2006 and close on April 17, 2006 ...

Plethico Pharmaceuticals IPO opens on April 10 - Gujarati ...

Issue proceeds to fund acquisitions
The company is focusing on entering the European markets, which it feels will give it a perfect launching pad for its operations into the US ...

Plethico Pharma files IPO draft prospectus
Plethico Pharmaceuticals Ltd. on Tuesday filed its draft prospectus for its maiden public issue with SEBI. The IPO is to raise Rs. 100 crore ...

Plethico Pharma eyes CIS nations
Emerging global healthcare company Plethico Pharmaceuticals Ltd has made the Commonwealth of Independent States (CIS) nations, which are untapped markets with ...

Leader Speak
Plethico Pharmaceuticals Ltd was established in 1985 to augment a focused approach towards global brand marketing. Plethico has ...

Plethico builds drugs chest with lifestyle brands ...
Aiming to make a big splash in the pharma segment when its non-compete agreement with Shreya Life Sciences expires in 2007-08, Plethico Pharmaceuticals Ltd is ...

Plethico in talks with Citi, CLSA for stake dilution
Two leading private equity players namely Citicorp and CLSA are in talks with Plethico Pharmaceuticals for acquiring nearly 10 per per cent stake in the export ...

Plethico looking at options to fund growth plans
Having restructured itself to grow in the non-infringing segments, the company is preparing for its next level of growth, targeting Rs. 1,000 crore by 2010 ...

Disclaimer

"Third party web sites and information provided on third party websites are not part of the Plethico website and Plethico will not accept any responsibility or liability for their content, accuracy or availability. In addition, any articles or information in relation to Plethico on or from such third party sources do not necessarily reflect the views of Plethico and Plethico is not responsible for the contents of any such articles or information.

Plethico reserves the right to change, delete or move any of the material on this website at any time without notice."